Cordycepin inhibits kidney injury by regulating GSK‐3β‐mediated Nrf2 activation

• Published in: Journal of biochemical and molecular toxicology 2024-01, Vol.38 (1), p.e23600-n/a
• Main Authors: Tang, Zhiling, Chen, Kean, Sun, Chun, Ying, Xiangjun, Li, Ming
• Format: Article
• Language: English
• Subjects: Cisplatin; Cordycepin; Ferroptosis; Glycogen; Glycogen synthase kinase 3; Glycogens; GSK‐3β; Histopathology; Injuries; Injury analysis; kidney injury; Kidneys; Kinases; Pharmacology
• ISSN: 1095-6670; 1099-0461
• DOI: 10.1002/jbt.23600

We explored the role and mechanism of cordycepin (COR) in inhibiting kidney injury. A mouse model of kidney injury was established using cisplatin (CDDP), and the kidney function, histopathology, and ferroptosis indices in mice were detected after intervening with COR. The targets of COR‐ferroptosis‐kidney injury were analyzed by network pharmacology, based on which the association between glycogen synthase kinase‐3 beta (GSK‐3β) and COR was determined. HK‐2 cells were cultured in vitro and treated separately with ferroptosis inducers erastin and CDDP. After the COR intervention, the level of ferroptosis was monitored. In vitro experiments found that COR could inhibit ferroptosis and CDDP‐induced kidney injury. Network pharmacological analysis revealed that GSK‐3β was the target of COR. After inhibiting GSK‐3β expression, COR could not further inhibit the occurrence of ferroptosis. In vitro results also indicated that COR could inhibit ferroptosis in HK‐2 cells. According to our findings, COR can ameliorate CDDP‐induced kidney injury through GSK‐3β‐mediated ferroptosis signaling. We identify new pharmacological effect and target for COR, the major component of Cordyceps sinensis.